Post-COVID Multisystem Inflammatory Syndrome in the Deployed Environment
Abstract
Cases of multisystem inflammatory syndrome after current or previous SARS-CoV-2 infection have been extensively documented in children. Although there has been recent recognition of a similar adult post-COVID entity known as multisystem inflammatory syndrome in adults (MIS-A), these cases have rarely been reported. This report describes the case of a soldier in the deployed setting with a benign initial clinical presentation who rapidly developed life-threatening MIS-A.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.